When was Atom Bioworks founded?

Atom Bioworks was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Atom Bioworks located?

Atom Bioworks is headquartered in Cary, United States.

Who is the current CEO of Atom Bioworks?

Sherwood Yao of Atom Bioworks. They have also founded 1 company.

How many employees does Atom Bioworks have?

As of Aug 31, 2026, the latest employee count at Atom Bioworks is 8.

Is Atom Bioworks a funded company?

Atom Bioworks is a funded company, having raised an undisclosed amount across 3 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 01, 2020.

When was the latest funding round of Atom Bioworks?

Atom Bioworks' latest funding was a $***** Grant (prize money) round on Mar 26, 2025, with participation from 1 investor. Its primary sector is Genomics. In United States, the Genomics sector has seen $2.39B in funding in 2026 to date.

Where does Atom Bioworks rank among its competitors?

Atom Bioworks ranks 15th amongst 43 active competitors, of which 14 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Seek Labs, which secured $2M in Feb, 2026.

Who are the top competitors of Atom Bioworks?

Atom Bioworks' top competitors include Cytonics, Circular Genomics and PierianDx. Among them, Seek Labs secured the most recent funding round in February, 2026.

Atom Bioworks - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of DNA nanostructures for various applications. The company has developed a platform for programming DNA and RNA-based biomolecules as high-affinity binding reagent for various applications, including drug delivery and diagnostics for infectious diseases and cancer. It also, offers AI enabled DNA design software system provides flexibility to design and manufacture nanometre-scale biomaterial.

Website: atombioworks.com
Email ID: *****@atombioworks.com

Key Metrics

Founded Year

2019

Location

Cary, United States

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Mar 26, 2025, $*****

Investors

Transolam & 4 more

Ranked

15^th among 43 active competitors

Employee Count

8 as on Aug 31, 2026

Similar Companies

Cytonics & 52 more

View Atom Bioworks' full profile

Atom Bioworks has raised funding over 3 rounds. Its first funding round was on Jun 01, 2020. Its latest funding round was a Grant (prize money) round on Mar 26, 2025 for $*****. 1 investor participated in its latest round. Atom Bioworks has 5 institutional investors.

Here is the list of recent funding rounds of Atom Bioworks:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 26, 2025	9006816	Grant (prize money)	5687391	5551872	3689737	4594947
Sep 06, 2022	1535920	Grant (prize money)	8926053	1737265	3373799	HHS
Jun 01, 2020	9174810	Grant (prize money)	4984597	1535216	7272459	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Atom Bioworks's funding rounds and investors

Atom Bioworks' employee count trend

Atom Bioworks has 8 employees as of Aug 26. Here is Atom Bioworks's employee count trend over the years:

Uncover Atom Bioworks' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Atom Bioworks include Cytonics, Circular Genomics and PierianDx. Here is the list of Top 10 competitors of Atom Bioworks, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Cytonics 2006, Jupiter (United States), Seed	Developer of biologic therapies targeting molecular drivers of cartilage degradation	$3.33M	NIH SBIR/STTR, HHS & 1 others	56/100
2nd	Circular Genomics 2021, Albuquerque (United States), Series A	Provider of RNA-based diagnostics and therapeutics to treat depression	$29M	Mountain Group Partners, Cottonwood Technology Fund ... & 3 others	55/100
3rd	PierianDx 2014, Saint Louis (United States), Acquired	Provider of genetic tests for individualized diagnosis of multiple diseases	$69.4M	ATW Partners, Orbimed & 12 others	53/100
4th	Ulisse BioMed 2015, Udine (Italy), Series B	Manufacturer of biological drug monitoring and molecular diagnostics	$17.6M	Europa, Global Corporate Finance	53/100
5th	Telix Pharma 2015, Melbourne (Australia), Public	Developer of theranostic radiopharmaceuticals for imaging and treating cancer	-	China Grand Pharmaceutical and Healthcare	52/100
6th	Ignyta 2011, San Diego (United States), Acquired	Personalized medicine for cancer and autoimmune diseases	$96.9M	Colt Ventures, City Hill Ventures & 7 others	51/100
7th	Seek Labs 2017, Salt Lake City (United States), Series B	Developer of a technology for the treatment and diagnostics of infectious diseases.	$13.6M	United States Department of Agriculture	49/100
8th	Treos Bio 2013, London (United Kingdom), Series B	Developer of cancer vaccines and companion diagnostics	$22M	Luminous Ventures, Hopkins Capital & 43 others	47/100
9th	NeuroBio 2013, Oxford (United Kingdom), Series A	UK-based, preclinical stage biopharma startup developing therapeutics for Alzheimer's disease.	$14.1M	Alcatt, P and S Yates & 59 others	43/100
10th	Xiantong Pharmaceutical 2004, Beijing (China), Series E	Developer of radiopharmaceuticals for the diagnosis of tumors, neurodegenerative diseases and cardiovascular diseases.	$99.5M	Goldstone Investment , SDIC & 13 others	42/100
15th	Atom Bioworks 2019, Cary (United States), Funding Raised	Developer of DNA nanostructures for various applications	-	Transolam, Gravity Fund & 3 others	33/100